Optimizing Maternal RSV Immunization Delivery: A Systems-Based Quality Improvement Initiative to Improve Uptake, Equity, and Newborn Outcomes
Pfizer Inc. funds quality improvement projects to advance maternal RSV immunization delivery, targeting barriers to uptake, equity, and newborn health through systems-based interventions.
Funder: Pfizer Inc.
Due Dates: September 17, 2026: Submission Deadline
Funding Amounts: Up to $200,000 total; $100,000 for single-site/regional, up to $200,000 for multi-site/broader projects; max project length 18 months.
Summary: Supports quality improvement projects to enhance maternal RSV immunization delivery, address barriers to uptake, and improve equity and newborn health outcomes in the U.S.
Key Information: Projects must focus on implementation and system/practice changes, not clinical research or efficacy studies.
Description
This grant opportunity, offered by Pfizer Inc. in collaboration with the Society for Maternal-Fetal Medicine (SMFM), seeks proposals for independent quality improvement (QI) initiatives that advance maternal immunization, specifically with a focus on Respiratory Syncytial Virus (RSV) vaccination during pregnancy. The program is designed to fund projects that implement evidence-based, scalable interventions to address clinical, behavioral, and system-level barriers to maternal RSV vaccine uptake. The goal is to improve access, provider-patient communication, care coordination, and equity in maternal immunization, ultimately reducing disparities and improving newborn outcomes.
Projects should employ real-world, data-driven approaches to enhance vaccine delivery and uptake, particularly in communities disproportionately affected by vaccine-preventable diseases and maternal care deserts. Educational initiatives are permitted but must be paired with system or practice change components to be competitive.
